ArticleMedical science monitor : international medical journal of experimental and clinical research2014
Identification of γ-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Evaluation of expression profiles of APOA4, CEACAM1, CD147, DJ-1/PARK7, Gamma-synuclein, S100A1, and Stathmin-1 in urothelial carcinomas using immunohistochemical assays.Frontiers in oncology · 2025Article
- Synuclein Proteins in Cancer Development and Progression.Biomolecules · 2023Review
- Gamma synuclein is a novel nicotine responsive protein in oral cancer malignancy.Cancer cell international · 2020Article
- The down-regulation of SNCG inhibits the proliferation and invasiveness of human bladder cancer cell line 5637 and suppresses the expression of MMP-2/9.International journal of clinical and experimental pathology · 2020Article
- The Dependence between Urinary Levels of Angiogenesis Factors, 8-Iso-prostaglandin F2Journal of oncology · 2020Article
- The clinical and prognostic value of miR-9 gene expression in Tunisian patients with bladder cancer.Molecular biology reports · 2019Article
- High Apelin Level Indicates a Poor Prognostic Factor in Muscle-Invasive Bladder Cancer.Disease markers · 2019Article
- The contemporary role and impact of urine-based biomarkers in bladder cancer.Translational andrology and urology · 2017Review
- The anti-melanoma activity and oncogenic targets of hsa-miR-15a-5p.RNA & disease (Houston, Tex.) · 2016Article
- Up-regulation of miR-9 target CBX7 to regulate invasion ability of bladder transitional cell carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have shown that the expression level of γ-synuclein (SNCG) is associated with progression of many different malignant tumors. In this study, we discuss and assess the prognostic ability of SNCG in bladder cancer. MATERIAL AND
methodsMedical records (2005-2013) were retrospectively reviewed for the population of interest. SNCG expression was identified immunohistochemically from bladder cancer tissues of 113 bladder cancer patients. The survival rate was calculated by the Kaplan-Meier method. Cox proportional hazard regression model was used for analysis of predictors of bladder cancer.
resultsSNCG was overexpressed in bladder cancer tissues compared with the normal bladder tissues (p<0.0001). SNCG expression in bladder cancer tissue was strongly related to tumor stage. However, SNCG level was not a prognostic factor of survival.
conclusionsOur results demonstrate that SNCG is highly expressed in bladder cancer tissue and its expression is stage-specific, but it is not helpful for predicting outcome in bladder cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.